Concepedia

Keiichi Masuya

KM

Statistics

Publications

27

Citations

1.2K

H-Index

20

Active since

1994

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Tokyo Institute of Technology

Peptidream (Japan)

Novartis (Japan)

Keiichi Masuya is an author at Novartis (Switzerland) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

1994–2023

27

Publications

27

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Philipp Holzer, Keiichi Masuya, Pascal Furet et al. · Journal of Medicinal Chemistry · 2015 · 206 citations · Full text

, , +15

Total Synthesis of (−)-Coriolin

Hajime Mizuno, Kei Domon, Keiichi Masuya et al. · The Journal of Organic Chemistry · 1999 · 98 citations

, , +12

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Sébastien Jeay, Swann Gaulis, Stéphane Ferretti et al. · eLife · 2015 · 87 citations · Full text

, , +17

Highly Regio- and Stereoselective [3+2] Cyclopentanone Annulation Using a 3-(Alkylthio)-2-siloxyallyl Cationic Species

Keiichi Masuya, Kei Domon, Keiji Tanino et al. · Journal of the American Chemical Society · 1998 · 81 citations

, , +11

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Pascal Furet, Keiichi Masuya, Joerg Kallen et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 79 citations

, , +10

1–5 of 27